Interaction Checker

Interacciones de Gefitinib

Gefitinib (Iressa) tiene 108 interacciones documentadas en las etiquetas de la FDA y las hojas informativas que indexamos. Graves: 8; moderadas: 100; leves: 0; casos en los que una etiqueta indica que no hay ninguna interacción significativa: 0. Cada entrada de abajo cita la frase que la respalda. Esta página del medicamento es un punto de partida, no un veredicto sobre su situación.

Interacciones según la etiqueta

Interacciones graves (8)

  • Dexlansoprazolinhibidor de la bomba de protonesGrave

    • Drugs Affecting Gastric pH: Avoid concomitant use of IRESSA with proton pump inhibitors, if possible. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • Esomeprazolinhibidor de la bomba de protonesGrave

    • Drugs Affecting Gastric pH: Avoid concomitant use of IRESSA with proton pump inhibitors, if possible. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • Lansoprazolinhibidor de la bomba de protonesGrave

    • Drugs Affecting Gastric pH: Avoid concomitant use of IRESSA with proton pump inhibitors, if possible. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • Naproxeno y esomeprazolAINEGrave

    • Drugs Affecting Gastric pH: Avoid concomitant use of IRESSA with proton pump inhibitors, if possible. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • Omeprazolinhibidor de la bomba de protonesGrave

    • Drugs Affecting Gastric pH: Avoid concomitant use of IRESSA with proton pump inhibitors, if possible. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • Omeprazol y bicarbonato de sodioinhibidor de la bomba de protonesGrave

    • Drugs Affecting Gastric pH: Avoid concomitant use of IRESSA with proton pump inhibitors, if possible. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • Pantoprazolinhibidor de la bomba de protonesGrave

    • Drugs Affecting Gastric pH: Avoid concomitant use of IRESSA with proton pump inhibitors, if possible. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • Rabeprazolinhibidor de la bomba de protonesGrave

    • Drugs Affecting Gastric pH: Avoid concomitant use of IRESSA with proton pump inhibitors, if possible. (etiqueta de Gefitinib, Interacciones medicamentosas)

Interacciones moderadas (100)

  • AmiodaronaantiarrítmicoModerada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • Amitriptilinaantidepresivo tricíclicoModerada

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (etiqueta de Gefitinib, Interacciones medicamentosas)

  • Amoxapinaantidepresivo tricíclicoModerada

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (etiqueta de Gefitinib, Interacciones medicamentosas)

  • Antiácidos (Tums, Maalox, Mylanta)Productos sin recetaModerada

    Drugs Affecting Gastric pH Drugs that elevate gastric pH (e.g., proton pump inhibitors, histamine H 2 -receptor antagonists, and antacids) may reduce plasma concentrations of gefitinib. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • Aprepitantinhibidor de CYP3A4Moderada

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • Armodafiniloestimulante del SNCModerada

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • AtazanavirantirretroviralModerada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • Bicarbonato de sodioantiácidoModerada

    Drugs Affecting Gastric pH Drugs that elevate gastric pH (e.g., proton pump inhibitors, histamine H 2 -receptor antagonists, and antacids) may reduce plasma concentrations of gefitinib. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • Bosentáninductor de CYP3A4Moderada

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • BupropiónantidepresivoModerada

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (etiqueta de Gefitinib, Interacciones medicamentosas)

  • CarbamazepinaanticonvulsivoModerada

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • CenobamatoanticonvulsivoModerada

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • CiclosporinainmunosupresorModerada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • Cimetidinaantagonista H2Moderada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • CitalopramISRSModerada

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (etiqueta de Gefitinib, Interacciones medicamentosas)

  • Claritromicinaantibiótico macrólidoModerada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • ClobazambenzodiazepinaModerada

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • Clomipraminaantidepresivo tricíclicoModerada

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (etiqueta de Gefitinib, Interacciones medicamentosas)

  • DarunavirantirretroviralModerada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • Darunavir y cobicistatantirretroviralModerada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • Deferasiroxsuplemento de hierroModerada

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • Desipraminaantidepresivo tricíclicoModerada

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (etiqueta de Gefitinib, Interacciones medicamentosas)

  • DesvenlafaxinaIRSNModerada

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (etiqueta de Gefitinib, Interacciones medicamentosas)

  • DexametasonacorticosteroideModerada

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • Diltiazembloqueador de los canales de calcioModerada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • Doxepinaantidepresivo tricíclicoModerada

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (etiqueta de Gefitinib, Interacciones medicamentosas)

  • DronedaronaantiarrítmicoModerada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • DuloxetinaIRSNModerada

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (etiqueta de Gefitinib, Interacciones medicamentosas)

  • EfavirenzantirretroviralModerada

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • Efavirenz, lamivudina y tenofovirantirretroviralModerada

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • Elvitegravir, cobicistat, emtricitabina y tenofovirantirretroviralModerada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • Eritromicinaantibiótico macrólidoModerada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • EscitalopramISRSModerada

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (etiqueta de Gefitinib, Interacciones medicamentosas)

  • EslicarbazepinaanticonvulsivoModerada

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • EtravirinaantirretroviralModerada

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • EverolimusinmunosupresorModerada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • Famotidinaantagonista H2Moderada

    Drugs Affecting Gastric pH Drugs that elevate gastric pH (e.g., proton pump inhibitors, histamine H 2 -receptor antagonists, and antacids) may reduce plasma concentrations of gefitinib. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • Fenelzinainhibidor de la MAOModerada

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (etiqueta de Gefitinib, Interacciones medicamentosas)

  • FenitoínaanticonvulsivoModerada

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • FenobarbitalbarbitúricoModerada

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • Fentermina y topiramatoestimulante del SNCModerada

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • Fluconazolantifúngico azólicoModerada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • FluoxetinaISRSModerada

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (etiqueta de Gefitinib, Interacciones medicamentosas)

  • FluvoxaminaISRSModerada

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (etiqueta de Gefitinib, Interacciones medicamentosas)

  • FosamprenavirantirretroviralModerada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • Fosaprepitantinhibidor de CYP3A4Moderada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • FosfenitoínaanticonvulsivoModerada

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • GriseofulvinaantifúngicoModerada

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • Ibuprofeno y famotidinaAINEModerada

    Drugs Affecting Gastric pH Drugs that elevate gastric pH (e.g., proton pump inhibitors, histamine H 2 -receptor antagonists, and antacids) may reduce plasma concentrations of gefitinib. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • Imatinibinhibidor de CYP3A4Moderada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • Imipraminaantidepresivo tricíclicoModerada

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (etiqueta de Gefitinib, Interacciones medicamentosas)

  • IsoniazidaantibióticoModerada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • Itraconazolantifúngico azólicoModerada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • Ivacaftorinhibidor de CYP3A4Moderada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • Ketoconazolantifúngico azólicoModerada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • LenacapavirantirretroviralModerada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • LevomilnacipránIRSNModerada

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (etiqueta de Gefitinib, Interacciones medicamentosas)

  • Lopinavir y ritonavirantirretroviralModerada

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • Lorlatinibinductor de CYP3A4Moderada

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • Mifepristonainhibidor de CYP3A4Moderada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • Mirabegrónagonista beta-adrenérgicoModerada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • MirtazapinaantidepresivoModerada

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (etiqueta de Gefitinib, Interacciones medicamentosas)

  • Mitapivatinductor de CYP3A4Moderada

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • Mitotanoinductor de CYP3A4Moderada

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • Modafiniloestimulante del SNCModerada

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • Nafcilinaantibiótico del grupo de las penicilinasModerada

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • Naltrexona y bupropiónantagonista opioideModerada

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (etiqueta de Gefitinib, Interacciones medicamentosas)

  • NefazodonaantidepresivoModerada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • NevirapinaantirretroviralModerada

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • Nirmatrelvir y ritonavirantiviralModerada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • Nizatidinaantagonista H2Moderada

    Drugs Affecting Gastric pH Drugs that elevate gastric pH (e.g., proton pump inhibitors, histamine H 2 -receptor antagonists, and antacids) may reduce plasma concentrations of gefitinib. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • Nortriptilinaantidepresivo tricíclicoModerada

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (etiqueta de Gefitinib, Interacciones medicamentosas)

  • Olanzapina y fluoxetinaantipsicóticoModerada

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (etiqueta de Gefitinib, Interacciones medicamentosas)

  • OxcarbazepinaanticonvulsivoModerada

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • Palbociclibinhibidor de CYP3A4Moderada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • ParoxetinaISRSModerada

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (etiqueta de Gefitinib, Interacciones medicamentosas)

  • PerampanelanticonvulsivoModerada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • Posaconazolantifúngico azólicoModerada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • PrimidonaanticonvulsivoModerada

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • Protriptilinaantidepresivo tricíclicoModerada

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (etiqueta de Gefitinib, Interacciones medicamentosas)

  • Ranitidinaantagonista H2Moderada

    Drugs Affecting Gastric pH Drugs that elevate gastric pH (e.g., proton pump inhibitors, histamine H 2 -receptor antagonists, and antacids) may reduce plasma concentrations of gefitinib. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • Ranolazinafármaco que prolonga el intervalo QTModerada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • RifabutinaantibióticoModerada

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • RifampicinaantibióticoModerada

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • RifapentinaantibióticoModerada

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • RitonavirantirretroviralModerada

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • SertralinaISRSModerada

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (etiqueta de Gefitinib, Interacciones medicamentosas)

  • Suvorexantsedante-hipnóticoModerada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • Suzetriginainductor de CYP3A4Moderada

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • Ticagrelorantiagregante plaquetarioModerada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • TopiramatoanticonvulsivoModerada

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • Tranilciprominainhibidor de la MAOModerada

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (etiqueta de Gefitinib, Interacciones medicamentosas)

  • TrazodonaantidepresivoModerada

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (etiqueta de Gefitinib, Interacciones medicamentosas)

  • Trimipraminaantidepresivo tricíclicoModerada

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (etiqueta de Gefitinib, Interacciones medicamentosas)

  • VenlafaxinaIRSNModerada

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (etiqueta de Gefitinib, Interacciones medicamentosas)

  • Verapamilobloqueador de los canales de calcioModerada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • VilazodonaISRSModerada

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (etiqueta de Gefitinib, Interacciones medicamentosas)

  • Voriconazolantifúngico azólicoModerada

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (etiqueta de Gefitinib, Interacciones medicamentosas)

  • VortioxetinaantidepresivoModerada

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (etiqueta de Gefitinib, Interacciones medicamentosas)

  • WarfarinaanticoagulanteModerada

    • Hemorrhage in patients taking warfarin: Monitor changes in prothrombin time or INR. (etiqueta de Gefitinib, Interacciones medicamentosas)

Compruebe Gefitinib frente a todo lo que toma. Añada su lista completa; todos los pares se comprueban a la vez.

Abrir en el verificador

No es un consejo médico. La gravedad refleja la redacción de la etiqueta, no sus circunstancias. Una señal «grave» puede ser algo habitual bajo supervisión y una «leve» puede ser importante a dosis altas. Consulte a un farmacéutico.